immunotherapy
In a significant move to expand its immuno-oncology portfolio, Boehringer Ingelheim has acquired T3 Pharmaceuticals AG, a Swiss biotech company specializing in bacterial cancer therapy.
The findings show that bacterial metabolites can sensitize cancer cells to treatment with immunotherapy by boosting the expression of HLA class I molecules.
Understanding how antibiotics influence the microbiota’s impacts on immunotherapy may inform strategies to identify cancer patients that are more likely to respond to cancer treatment.
The findings of a recent study suggest that FMT is an effective strategy to mitigate the intestinal side effects of cancer immunotherapy.
Pedro Correa de Sampaio, Chief Executive Officer at Neobe Therapeutics, talks about the challenges to remove immunosuppressive constraints that prevent the infiltration of immune cells in a subset of cancers.
The findings of a recent study suggest that targeting the interactions between MAdCAM-1 and specific receptors on the surface of immune cells may help to improve immunotherapy outcomes.
The findings of a recent study identified microbiota signatures that may allow clinicians to predict the outcomes of CAR-T immunotherapy.
Numerous evidences demonstrate the involvement of the sex hormone-gut microbiome axis in regulating the antitumor efficacy of ICIs.
The findings of a new study shed light on a general mechanism by which gut bacteria may influence anti-cancer immune responses.
Fabio Grassi, Founder at MV BioTherapeutics SA, discussed how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.
